PCM
DSGN icon

Pinz Capital Management’s Design Therapeutics DSGN Stock Holding History

Pinz Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,338
Closed -$86K – 207
2021
Q2 		$86K Buy
+4,338
New +$109K 0.03% 272

Other funds holding DSGN

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pinz Capital Management's DSGN Position: Q3 2021 in Review

Pinz Capital Management sold out of Design Therapeutics (DSGN) in Q3 2021, closing a stake of 4,338 shares — an estimated $86K sold.

Pinz Capital Management first reported a position in DSGN in Q2 2021 and held it in 1 quarter. The position peaked at $86K in Q2 2021. 52 funds tracked by Wall St. Rank hold DSGN as of Q3 2021.

  • Pinz Capital Management reported no remaining Design Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Pinz Capital Management sold 4,338 Design Therapeutics shares in Q3 2021, an estimated $86K.
  • Pinz Capital Management first reported a position in Design Therapeutics in Q2 2021 and held it in 1 quarter.
  • Pinz Capital Management's Design Therapeutics position peaked at $86K in Q2 2021.
  • 52 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2021.

Based on Pinz Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.